Renal protective effects of tofogliflozin and changes in clinical parameters affecting renal function in patients with type 2 diabetes
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000048277
- Lead Sponsor
- Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital
- Brief Summary
The BW, BP, UP and serum UA decreased from baseline in both eGFR groups while the Hb increased. The eGFR did not significantly differ over time. The change in the eGFR at 12 months after the initiation of tofogliflozin was -1.9 and 0.2 mL/min/1.73 m2 in the normal- and low-eGFR group, respectively. In the normal-eGFR group, the change in the eGFR showed a significant negative correlation with the HbA1c and eGFR at baseline.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 158
Not provided
1. Tofogliflozin had already administered at the initial consultation 2. Patients who discontinued treatment or who were transferred to other hospitals during the observation period 3. Patient after renal transplantation 4. Iron preparations were started during the observation period 5. GLP-1 receptor agonists were started during the observation period 6. Antihypertensive agents, diuretics or urate lowering agents were changed during the observation period
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method changes in estimated glomerular filtration rate before and after the initiation of tofogliflozin
- Secondary Outcome Measures
Name Time Method